PREVENTION & EARLY DETECTION
WHERE TO FIND US
• The Christie NHS Foundation Trust
• MCRC building
• The University of Manchester
• MFT - Wythenshawe
The prevention and early detection of cancer is vital for improving survival rates in Greater Manchester. More of our population smoke and fewer take part in screening than the national average, and many cancers here are diagnosed by emergency presentation. We are carrying out innovative projects that aim to have an impact both here and elsewhere.
In lung cancer, we have led screening pilot studies in high-risk populations within deprived areas and demonstrated that we are able to shift diagnosis towards an earlier stage, where curative treatment is more likely. This programme is now being rolled out in other areas of Greater Manchester and across northern England. We will continue to use the potential of the local population as cohorts for national and international screening and early detection studies (pre- and post-diagnosis settings).
In parallel, we are assessing the potential of circulating tumour-derived and inflammatory biomarkers to understand and then detect early lung disease. Our scientists are working in partnership with community pharmacy teams to enable people to have repeated blood tests close to home. We also hope to define inflammation and immune cell biology in relation to genomic and proteomic biomarkers of early detection in breast and endometrial cancers.
We are investigating the link between obesity and a range of malignancies, including colorectal, breast and endometrial cancer. Our researchers are developing non-invasive tools to measure fat deposition and to better characterise the observable features that lead to obesity-related cancer. We also have an interest in the role of co-morbidities, such as type 2 diabetes, in increasing the risk of both obesity-related and non obesity-related cancers.
Our breast cancer group is improving risk prediction and stratification, for both those at screening age and younger women. Within the PROCAS studies we are combining genetic information, mammographic density and patient questionnaires to provide women with an accurate, personalised risk assessment.
We also have expertise in inherited cancers such as BRCA-positive breast cancer and ovarian cancer, and are tracking how increased public awareness leads to uptake of preventive surgery.
Informatics & Data Sciences